Celularity Inc
For the period ended Dec 31, 2024. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed May 8, 2025
CELU$0.71-6.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flow
(In thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flow from operating activities: | ||
| Net loss | $(57,892) | $(196,295) |
| Adjustments to reconcile net loss to net cash used in operations: | ||
| Depreciation and amortization | 7,922 | 9,324 |
| Non cash lease expense | 160 | (13) |
| Provision for credit losses | 457 | 1,233 |
| Provision for inventory obsolescence | (186) | 1,328 |
| Change in fair value of warrant liabilities | (398) | (6,164) |
| Inventory impairment | 466 | 5,384 |
| Goodwill impairment | — | 112,347 |
| IPR&D impairment | — | 107,800 |
| Stock-based compensation expense | 11,569 | 15,017 |
| Change in fair value of contingent consideration | (193) | (104,339) |
| Acquired in-process research and development | — | 3,000 |
| Issuance of common stock for stem-cells to be used in research and development | — | 1,000 |
| Issuance of common stock to Palantir as consideration for settlement agreement | 175 | — |
| Issuance of common stock to Yorkville for debt extension and SEPA commitment fee | 317 | 712 |
| Issuance of common stock as compensation expense | 158 | — |
| Discounts arising from RWI loan arrangement - related party | — | 2,151 |
| Fair value of warrant modification for professional services | — | 403 |
| Loss on debt extinguishment | 3,908 | — |
| Change in fair value of debt | 492 | 1,177 |
| Change in fair value of contingent stock consideration | — | (159) |
| Non cash interest expense | 4,144 | — |
| Other, net | 300 | 4,157 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (3,968) | (6,827) |
| Inventory | 6,284 | (865) |
| Prepaid expenses and other assets | 905 | 5,606 |
| Accounts payable | 9,239 | 8,497 |
| Accrued expenses and other liabilities | 12,634 | (1,128) |
| Accrued R&D software | (3,500) | (3,834) |
| Lease liabilities - operating | 371 | 275 |
| Deferred revenue | 235 | 1,528 |
| Net cash used in operating activities | (6,401) | (38,685) |
| Cash flow from investing activities: | ||
| Capital expenditures | (161) | (1,048) |
| Rebound asset acquisition | (1,500) | — |
| Purchase of acquired in-process research and development | — | (3,000) |
| Proceeds from Sanuwave convertible note | 2,175 | — |
| Net cash provided by (used in) investing activities | 514 | (4,048) |
| Cash flow from financing activities: | ||
| Proceeds from warrants and short-term debt - related parties | 15,000 | 18,369 |
| Repayments of short-term debt - unaffiliated | (17,374) | (16,811) |
| Proceeds from the sale of common stock in ATM offering | — | 136 |
| Proceeds from issuance of short-term debt - unaffiliated | 3,622 | 2,000 |
| Payment of SEPA commitment fee | (25) | — |
| Repayments of short-term debt - related parties | (146) | — |
| Proceeds from PIPE financing | 6,000 | 12,750 |
| Proceeds from the exercise of stock options | 58 | 304 |
| Tax withholding on vesting of restricted stock units | (434) | (101) |
| Proceeds from registered direct offering | — | 9,000 |
| Payments of PIPE and other issuance costs | — | (1,553) |
| Net cash provided by financing activities | 6,701 | 24,094 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 814 | (18,639) |
| Cash, cash equivalents and restricted cash at beginning of year | 10,163 | 28,802 |
| Cash, cash equivalents and restricted cash at end of year | $10,977 | $10,163 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $144 | $1,073 |
| Supplemental non-cash investing and financing activities: | ||
| Property and equipment included in accounts payable and accrued expenses | $(87) | $(223) |
| Common stock issued for short-term debt conversion | $1,700 | $4,599 |
| Modification of C.V. Starr warrants in connection with forbearance | $51 | $— |
| Issuance of RWI warrants in connection with forbearance | $1,162 | $— |
| Issuance of warrants on senior secured bridge loan | $— | $2,002 |
| Reduction of right-of-use assets and associated lease liabilities - operating due to lease modification | $— | $(2,083) |
| PIPE related costs included in accrued expenses | $— | $(69) |
| Interest accrued on senior secured loans within long-term debt - related parties | $— | $(1,770) |
| Contingent consideration accrued in connection with Rebound asset acquisition | $650 | $— |
| Inventory acquired in connection with Rebound asset acquisition | $2,150 | $— |
| Reclassification of warrants from liability classified to equity classified | $2,970 | $— |
| Assumption of short-term debt - unaffiliated by related party | $2,333 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.